At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Simvastatin +3 moredrug
Likely dose
Simvastatin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome
In Brief
A Phase 4 clinical trial evaluating Simvastatin, Vytorin, and 2 other interventions for Metabolic Syndrome. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is: * To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. * To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
Primary CompletionFeb 2008
First PostedOct 2009
TodayJul 2026
First PostedOct 2, 2009
Enrollment StartMar 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.8 years ago
Interventions
Simvastatindrug
Simvastatin 20mg daily for 3 months.
Vytorindrug
Vytorin 20/10mg daily for 3 months.
Placebodrug
Placebo one tablet daily times 3 months.
Ezetimibedrug
Ezetimibe 10mg daily for 3 months.